DexCom, Inc. (DXCM) Upgraded at Zacks Investment Research
DexCom (NASDAQ:DXCM) opened at 73.06 on Monday. DexCom has a 12-month low of $57.68 and a 12-month high of $96.38. The company’s market capitalization is $6.32 billion. The company has a 50 day moving average price of $70.72 and a 200-day moving average price of $74.97.
DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. DexCom’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.24) EPS. On average, analysts anticipate that DexCom will post ($0.77) EPS for the current year.
TRADEMARK VIOLATION WARNING: “DexCom, Inc. (DXCM) Upgraded at Zacks Investment Research” was posted by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://baseballnewssource.com/markets/dexcom-inc-dxcm-upgraded-at-zacks-investment-research/1489909.html.
In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $69.06, for a total value of $220,992.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Richard Doubleday sold 3,182 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the sale, the executive vice president now owns 72,395 shares in the company, valued at $4,943,854.55. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,726 shares of company stock worth $2,376,466. 1.70% of the stock is owned by insiders. Hedge funds have recently modified their holdings of the stock. Advisor Group Inc. raised its stake in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of DexCom during the first quarter valued at about $136,000. IFP Advisors Inc raised its stake in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom during the first quarter valued at about $164,000. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Get a free copy of the Zacks research report on DexCom (DXCM)
Rothschild Capital Partners Trimmed Its Dexcom (DXCM) Holding ...
San Times-3 minutes ago
Rothschild Capital Partners Llc decreased Dexcom Inc (DXCM) stake by 12.39% reported in 2016Q4 SEC filing. Rothschild Capital Partners Llc sold 8,185 ...
DexCom, Inc. (DXCM) Rating Reiterated by Piper Jaffray Companies
Markets Daily-6 hours ago
DexCom logo DexCom, Inc. (NASDAQ:DXCM)'s stock had its “overweight” rating reissued by stock analysts at Piper Jaffray Companies in a research note ...
___________________________________________________________________________________
Earnings Review and Free Research Report: DexCom’s Q2 Top-line Surged 24%; Outshined Forecasts
By AccessWire, August 17, 2017, 07:20:00 AM EDT
LONDON, UK / ACCESSWIRE / August 17, 2017 /Pro-Trader Daily has just published a free post-earnings coverage on DexCom, Inc. (NASDAQ:DXCM), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=DXCM, following the Company's reporting of its financial results on August 01, 2017, for the second quarter fiscal 2017 (Q2 FY17). The San Diego, California-based Company's quarterly total revenues grew 24% y-o-y, outperforming market consensus estimates. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:http://protraderdaily.com/register/
Get more of our free earnings reports coverage from other constituents of the Medical Laboratories & Research industry. Pro-TD has currently selected PRA Health Sciences, Inc. (NASDAQ:PRAH) for due-diligence and potential coverage as the Company reported on August 07, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on PRA Health Sciences when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on DXCM; also brushing on PRAH. With the links below you can directly download the report of your stock of interest free of charge at:
http://protraderdaily.com/optin/?symbol=DXCM
http://protraderdaily.com/optin/?symbol=PRAH
Earnings Reviewed
During the quarter ended on June 30, 2017, DexCom's total revenues increased to $170.6 million from $137.3 million recorded at the end of Q2 FY16. Total revenue numbers for Q2 FY17 also topped market consensus estimates of $166.2 million.
The developer and marketer for glucose monitoring systems reported net income of $2.9 million, or $0.03 per diluted share, in Q2 FY17 versus net loss of $20.2 million, or $0.24 per diluted share, in Q2 FY16. Meanwhile, the Company's non-GAAP net loss narrowed to $14.2 million, or $0.16 per diluted share, during Q2 FY17 from non-GAAP net loss $20.2 million, or $0.24 per diluted share, in the prior year's comparable quarter. Meanwhile, Wall Street had expected the Company to report non-GAAP net loss of $0.23 per share.
Operational Metrics
For the reported quarter, the Company's gross profit increased $117.5 million, or 69% of total revenues, from $85.5 million, or 62% of total revenues, in the prior year's same quarter. During Q2 FY17, the Company's research and development expenses increased to $45.3 million from $36.3 million in Q2 FY16. The Company's selling, general, and administrative expenses (SG&A) came in at $85.8 million during Q2 FY17 compared to $69.3 million in the previous year's corresponding quarter. The increase in SG&A during Q2 FY17 is primarily due to year-over-year increase in head count in of the Company's customer support organizations as well as the continued commercialization of products in both the United States and Europe.
The Company reported operating loss of $13.6 million during Q2 FY17 compared to operating loss of $20.1 million in Q2 FY16. Furthermore, the Company's loss before income taxes narrowed to $14.4 million during Q2 FY17 compared to loss before income taxes of $20.1 million in Q2 FY16.
Revenues Metrics
By Component -In Q2 FY17, Sensor revenues were up by 27% to $120.7 million y-o-y, contributing 71% to the Company's total revenues. Transmitter revenue grew 23% to $34.7 million y-o-y in Q2 FY17, which was 20% of the total revenues earned by the Company during the reported period. Furthermore, Receiver revenue comprised 8% of the Company total revenues in Q2 FY17 and it rose 7% to $14.0 million y-o-y during the reported quarter.
By Geographical Region -DexCom's US revenue grew 18% y-o-y to $140.8 million in Q2 FY17, contributing 83% to the Company's total revenues. Additionally, OUS (Outside US) revenue surged 69% to $29.7 million y-o-y in Q2 FY17.
Cash Flow & Balance Sheet
During first six months of FY17, DexCom's net cash provided by operating activities were $14.6 million versus $19.9 million in H1 FY16. At the close of books in the reported quarter, DexCom had $395.9 million in cash and cash equivalents compared to $94.5 million at the close of books on December 31, 2016. Additionally, the Company reported long-term senior convertible notes amounting to $320.5 million in its books of accounts as on June 30, 2017.
Stock Performance
On Wednesday, August 16, 2017, the stock closed the trading session at $73.06, climbing 2.58% from its previous closing price of $71.22. A total volume of 752.12 thousand shares have exchanged hands. DexCom's stock price advanced 4.42% in the last one month and 7.36% in the past three months. Furthermore, since the start of the year, shares of the Company have surged 22.38%. The stock currently has a market cap of $6.34 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
No comments:
Post a Comment